Plk Inhibitors
Items 11 to 15 of 15 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Polo-like Kinase Inhibitor III | 660868-91-7 | sc-203202 | 500 µg | $107.00 | 1 | |
Polo-like kinase inhibitors, such as Polo-like Kinase Inhibitor III, work by targeting and inhibiting the activity of polo-like kinases (PLKs). PLKs are a family of serine/threonine protein kinases that play a crucial role in cell division and cell cycle progression. By inhibiting PLKs, Polo-like Kinase Inhibitor III disrupts the normal cell cycle progression, leading to cell cycle arrest and inhibition of cell proliferation. | ||||||
GSK461364 | 929095-18-1 | sc-364504 sc-364504A | 10 mg 50 mg | $500.00 $1540.00 | ||
GSK461364 is a small molecule inhibitor that targets PLK (Polo-like kinase) by binding to the ATP-binding pocket of the kinase's active site. By occupying this site, GSK461364 prevents the transfer of phosphate groups to substrates, effectively inhibiting PLK's catalytic activity. As a consequence, the normal cell cycle progression and mitotic processes in cancer cells are disrupted, leading to impaired cell division and potential cell death. | ||||||
HMN-214 | 173529-46-9 | sc-364507 sc-364507A | 5 mg 50 mg | $255.00 $1455.00 | ||
HMN-214 is a selective PLK1 (Polo-like kinase 1) inhibitor. It functions by directly binding to the ATP-binding pocket of PLK1, thus inhibiting its kinase activity. PLK1 is a critical regulator of the cell cycle, especially during mitosis. By blocking its activity, HMN-214 disrupts the orderly progression of mitosis in cancer cells, leading to cell cycle arrest and ultimately, cell death. | ||||||
A66 | 1166227-08-2 | sc-364394 sc-364394A | 5 mg 50 mg | $255.00 $1455.00 | ||
A66 functions as a Plk, distinguished by its capacity to disrupt typical phosphorylation cascades through targeted interactions with mitotic substrates. Its unique structural motifs enable it to stabilize transient protein complexes, thereby influencing cell cycle checkpoints. The compound exhibits a remarkable affinity for specific amino acid residues, which accelerates its reaction kinetics. Additionally, A66's selective reactivity with various cellular components highlights its role in modulating intricate signaling networks. | ||||||
AZD6482 | 1173900-33-8 | sc-364422 sc-364422A | 5 mg 10 mg | $275.00 $390.00 | 1 | |
AZD6482 is a selective PLK1 inhibitor designed to target the ATP-binding site of the kinase. When AZD6482 interacts with PLK1, it disrupts the kinase's ability to phosphorylate substrates, affecting the regulation of cell cycle progression and mitotic processes. As a result, AZD6482 induces cell cycle arrest and interferes with mitotic spindle formation in cancer cells, potentially leading to their death. | ||||||